Across TCGA pan-cancer cohorts, CROCC2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CROCC2 data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CROCC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CROCC2 expression acts as an unfavorable survival marker.

LIHC, CESC, and SARC are the cancer types where CROCC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.051	0.772	<.001	27	view →
CESC	DFS	Median	II,III,IV	0.173	0.705	.028	6	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CROCC2 tumor-vs-normal RNA expression · all CROCC2 data types